The role of nuclear EpICD in extrahepatic cholangiocarcinoma: Association with β-catenin

International Journal of Oncology

Volumn 45, Issue 2, 2014, Pages 691-698

  Jachin, Sarangerel ^a   Bae, Jun Sang ^a   Sung, Jong Jin ^a   Park, Ho Sung ^a   Jang, Kyu Yun ^a   Chung, Myoung Ja ^a   Kim, Dae Gohn ^a   Moon, Woo Sung ^a  

^a Chonbuk National University   (South Korea)

Author keywords

Catenin; Cholangiocarcinoma; Epithelial cell adhesion molecule; Invasion

Indexed keywords

BETA CATENIN; CYCLIN D1; EPITHELIAL CELL ADHESION MOLECULE; MYC PROTEIN; SMALL INTERFERING RNA; UVOMORULIN; CELL ADHESION MOLECULE; CTNNB1 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR-ASSOCIATED ANTIGEN GA733;

ARTICLE; BILE DUCT CARCINOMA; CANCER GRADING; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR INVASION; WESTERN BLOTTING; BILE DUCT TUMOR; CELL NUCLEUS; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HEPATIC DUCT; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN TRANSPORT; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; BETA CATENIN; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BLOTTING, WESTERN; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CHOLANGIOCARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM INVASIVENESS; PROTEIN TRANSPORT; TRANSFECTION;

EID: 84902579783     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2472     Document Type: Article

References (35)

1. Litvinov SV, Balzar M, Winter MJ, et al: Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 139: 1337-1348, 1997. (Pubitemid 27523219)
2. Baeuerle PA and Gires O: EpCAM (CD326) finding its role in cancer. Br J Cancer 96: 417-423, 2007. (Pubitemid 46215211)
3. Went PT, Lugli A, Meier S, et al: Frequent EpCam protein expression in human carcinomas. Hum Pathol 35: 122-128, 2004. (Pubitemid 38133932)
4. Munz M, Baeuerle PA and Gires O: The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 69: 5627-5629, 2009.
5. Patriarca C, Macchi RM, Marschner AK and Mellstedt H: Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 38: 68-75, 2012.
6. Schmidt M, Scheulen ME, Dittrich C, et al: An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol 21: 275-282, 2010.
7. Niedzwiecki D, Bertagnolli MM, Warren RS, et al: Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. J Clin Oncol 29: 3146-3152, 2011.
8. Maetzel D, Denzel S, Mack B, et al: Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 11: 162-171, 2009.
9. Ralhan R, He HC, So AK, et al: Nuclear and cytoplasmic accumulation of Ep-ICD is frequently detected in human epithelial cancers. PLoS One 5: e14130, 2010.
10. Carpenter G and Red Brewer M: EpCAM: another surface-to-nucleus missile. Cancer Cell 15: 165-166, 2009.
11. Schmalhofer O, Brabletz S and Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 28: 151-166, 2009.
12. Polette M, Mestdagt M, Bindels S, et al: Beta-catenin and ZO-1: shuttle molecules involved in tumor invasion-associated epithelial-mesenchymal transition processes. Cells Tissues Organs 185: 61-65, 2007. (Pubitemid 46956844)
13. Vincan E and Barker N: The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis 25: 657-663, 2008.
14. Paul S and Dey A: Wnt signaling and cancer development: therapeutic implication. Neoplasma 55: 165-176, 2008.
15. Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet 366: 1303-1314, 2005. (Pubitemid 41416587)
16. Blechacz B and Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48: 308-321, 2008. (Pubitemid 351975555)
17. van der Gaag NA, Kloek JJ, de Bakker JK, et al: Survival analysis and prognostic nomogram for patients undergoing resection of extrahepatic cholangiocarcinoma. Ann Oncol 23: 2642-2649, 2012.
18. Kim DG, Park SY, You KR, et al: Establishment and characterization of chromosomal aberrations in human cholangiocarcinoma cell lines by cross-species color banding. Genes Chromosomes Cancer 30: 48-56, 2001.
19. Bae JS, Noh SJ, Jang KY, et al: Expression and role of epithelial cell adhesion molecule in dysplastic nodule and hepatocellular carcinoma. Int J Oncol 41: 2150-2158, 2012.
20. Kwon CY, Kim KR, Choi HN, et al: The role of serum response factor in hepatocellular carcinoma: Implications for disease progression. Int J Oncol 37: 837-844, 2010.
21. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ and Warnaar SO: Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J Cell Biol 125: 437-446, 1994. (Pubitemid 24135956)
22. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM and Rots MG: EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31: 1913-1921, 2010.
23. Trzpis M, McLaughlin PM, de Leij LM and Harmsen MC: Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 171: 386-395, 2007. (Pubitemid 47344671)
24. Ralhan R, Cao J, Lim T, Macmillan C, Freeman JL and Walfish PG: EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer 10: 331, 2010.
25. Warneke VS, Behrens HM, Haag J, et al: Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis. Br J Cancer 109: 2217-2227, 2013.
26. Fong D, Moser P, Kasal A, et al: Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer. Histopathology 64: 683-692, 2014.
27. Lin CW, Liao MY, Lin WW, Wang YP, Lu TY and Wu HC: Epithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming factors and epithelial-mesenchymal transition gene expression in colon cancer. J Biol Chem 287: 39449-39459, 2012.
28. Gosens MJ, van Kempen LC, van de Velde CJ, van Krieken JH and Nagtegaal ID: Loss of membranous Ep-CAM in budding colorectal carcinoma cells. Mod Pathol 20: 221-232, 2007. (Pubitemid 46422177)
29. Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67, 2010.
30. Denzel S, Mack B, Eggert C, et al: MMP7 is a target of the tumour-associated antigen EpCAM. Int J Exp Pathol 93: 341-353, 2012.
31. Litvinov SV, van Driel W, van Rhijn CM, et al: Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 148: 865-875, 1996. (Pubitemid 126660678)
32. Chaves-Pérez A, Mack B, Maetzel D, et al: EpCAM regulates cell cycle progression via control of cyclin D1 expression. Oncogene 32: 641-650, 2013.
33. Osta WA, Chen Y, Mikhitarian K, et al: EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64: 5818-5824, 2004. (Pubitemid 39095582)
34. Yamashita T, Ji J, Budhu A, et al: EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136: 1012-1024, 2009.
35. Münz M, Kieu C, Mack B, Schmitt B, Zeidler R and Gires O: The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23: 5748-5758, 2004. (Pubitemid 39093020)